Would you recommend adjuvant androgen receptor–targeted therapy with enzalutamide or bicalutamide in a patient with pT2N0 TNBC with 100% AR expression and low Ki-67?
If she instead presented with metastatic disease, how, if at all, would you incorporate anti-androgen therapy into her treatment regimen?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on
The combination of 100% AR positivity and low Ki-67 is highly suggestive of the luminal androgen receptor (LAR) subtype, which represents 11 to 23 % of TNBC. Important features of this subtype include androgen receptor expression, luminal-like gene signatures, and a biology that fundamentally differ...
Join for free or sign in to see the full answer